Skip to main content

BioNTech

BioNTech SE is a German biotechnology company pioneering messenger RNA (mRNA) therapeutics and individualized cancer immunotherapies. The company structures its operational focus on mRNA drug platforms, cell therapies, and antibody-drug conjugates. Its commercial flagship product is the COVID-19 vaccine Comirnaty (developed with Pfizer), supported by an active clinical oncology pipeline. Primary revenue drivers are commercial vaccine sales, royalty sharing streams, and biopharmaceutical collaboration milestone payments. BioNTech holds a market-leading global position in mRNA-based vaccine development and therapeutic biotechnology. The company is headquartered in Mainz, Germany, and its American Depositary Shares (ADSs) trade on the Nasdaq Global Select Market.

14 of the funds FundTelligence covers report a position in BioNTech.

Legal name
BioNTech SE
Sector
Health Care
Country
Germany
Funds holding it
14
Exposure themes
Genetic Medicine, Precision Medicine & Genomics, RNA Therapeutics

Funds holding BioNTech

Showing the 8 largest of 14 funds holding it.

Loading...